Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M (Oktober 2008). »Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling«. Mol Cancer Ther. 7 (10): 3129–3140. PMID18852116.